List of Excipients in Branded Drug RUFINAMIDE

Generic Drugs Containing RUFINAMIDE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	rufinamide	0054-0425	1-PROPOXY-2-PROPANOL
Hikma Pharmaceuticals USA Inc	rufinamide	0054-0425	CELLULOSE, MICROCRYSTALLINE
Hikma Pharmaceuticals USA Inc	rufinamide	0054-0425	CROSCARMELLOSE SODIUM
Hikma Pharmaceuticals USA Inc	rufinamide	0054-0425	FERRIC OXIDE RED

What are the Most Frequently-Used Excipients in RUFINAMIDE?

# Of NDCs	Excipient
1	.ALPHA.-TOCOPHEROL, DL-
3	1-PROPOXY-2-PROPANOL
10	ANHYDROUS CITRIC ACID
1	CARBOXYMETHYLCELLULOSE

Rufinamide Excipient Strategy and Commercial Opportunities

Last updated: August 28, 2026

Rufinamide offers the strongest excipient opportunities in pediatric oral liquids, taste masking, dose uniformity, food-independent delivery, and differentiated multiparticulate products. The active pharmaceutical ingredient is used in Lennox-Gastaut syndrome and has limited aqueous solubility, while systemic exposure increases when administered with food. These properties create formulation value beyond a conventional immediate-release tablet.

The commercial opportunity is primarily generic and lifecycle-oriented. Brand exclusivity has expired in the United States, and formulation differentiation must rely on patient usability, bioequivalence execution, manufacturing efficiency, or intellectual-property features rather than the rufinamide molecule itself.

What is rufinamide and which dosage forms are commercially established?

Rufinamide is an antiseizure drug marketed in the United States as Banzel and in Europe as Inovelon. It is approved as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome in patients aged 1 year and older in the United States.[1]

Attribute	Rufinamide
Active ingredient	Rufinamide
Therapeutic class	Antiseizure medication
Primary indication	Lennox-Gastaut syndrome
U.S. brand	Banzel
U.S. dosage forms	200 mg and 400 mg tablets; 40 mg/mL oral suspension
European brand	Inovelon
Administration	Twice daily with food
Pediatric relevance	High, particularly for oral suspension
Primary formulation issue	Low aqueous solubility and palatability
Generic pathway	ANDA for tablets and oral suspension
Biologic risk	None; rufinamide is a small-molecule drug

Banzel tablets contain conventional solid-dose excipients, including microcrystalline cellulose, croscarmellose sodium, hypromellose, magnesium stearate, colloidal silicon dioxide, and sodium lauryl sulfate, according to the U.S. prescribing information.[1] The marketed suspension uses viscosity, suspension-stabilization, preservation, sweetening, and flavoring excipients appropriate for pediatric administration.

What excipient properties matter most for rufinamide?

The formulation strategy should address five technical variables: wetting, particle dispersion, sedimentation, taste, and administration with food.

Rufinamide is not a highly water-soluble compound. The marketed 40 mg/mL suspension therefore requires a dispersed-particle system rather than a simple aqueous solution. Excipient selection must maintain dose uniformity over the full dosing interval and prevent rapid settling or hard caking.

Food effects are also commercially relevant. FDA labeling reports that administration with food increases rufinamide exposure, with approximately 45% higher area under the concentration-time curve and approximately 56% higher maximum concentration compared with fasting administration.[1] A formulation that reduces dependence on meal timing could have clinical and commercial value, but it would require comparative pharmacokinetic evidence.

Target excipient functions

Formulation function	Potential excipient strategy	Commercial objective
Wetting and dispersion	Sodium lauryl sulfate or another suitable surfactant	Improve particle wetting and redispersion
Suspension stabilization	Microcrystalline cellulose-carboxymethylcellulose systems, xanthan gum, or other suspending polymers	Control sedimentation and dose uniformity
Viscosity control	Hypromellose, hydroxyethylcellulose, or xanthan gum	Limit settling without making the product difficult to pour
Taste masking	Sucralose, fruit flavor, ion-exchange resin, polymer coating, or lipid-based barrier	Improve pediatric acceptance
Preservation	Sodium benzoate or another validated preservative	Control microbial growth in multidose liquid
Solid-dose disintegration	Croscarmellose sodium, crospovidone, or sodium starch glycolate	Support rapid and reproducible tablet dispersion
Lubrication	Magnesium stearate or lower-impact alternatives	Improve tablet manufacture
Flow and compression	Colloidal silicon dioxide and microcrystalline cellulose	Improve manufacturing consistency

The preferred strategy depends on whether the product is intended to be an ANDA-equivalent product or a differentiated formulation. A standard generic should minimize excipient novelty because each added change increases regulatory and development complexity. A lifecycle product can justify a broader excipient platform if it improves adherence or solves a clinically meaningful administration problem.

What formulations are protected by the existing commercial product?

The established commercial products are immediate-release tablets and an oral suspension. Neither dosage form requires a complex modified-release system. The primary formulation distinction is therefore patient usability rather than prolonged delivery.

Immediate-release tablets

The tablet platform is relatively accessible to generic manufacturers. Key development variables include:

• API particle-size distribution
• surfactant level and wetting performance
• compression force
• disintegration time
• dissolution across pH conditions
• tablet friability
• dose proportionality between 200 mg and 400 mg strengths

A generic tablet can use a conventional direct-compression or dry-granulation process. The main risk is not basic manufacturability. It is reproducing dissolution and pharmacokinetic performance while managing a poorly soluble active ingredient and maintaining acceptable tablet size.

Oral suspension

The oral suspension presents a stronger differentiation opportunity. Critical quality attributes include:

• assay uniformity after shaking
• sedimentation rate
• redispersibility
• viscosity
• pourability
• preservative effectiveness
• microbial limits
• in-use stability
• container compatibility
• dosing-device accuracy
• taste and aftertaste

The 40 mg/mL concentration is commercially important because it reduces administration volume for pediatric patients. A lower concentration may improve pourability but increase the volume per dose. A higher concentration could reduce volume further, but it would increase suspension stability, palatability, and dose-uniformity challenges.

How can excipients improve pediatric commercial performance?

Pediatric acceptance is the most defensible commercial target for rufinamide excipient innovation. Rufinamide therapy can require substantial daily doses, especially in larger children and adults. A bitter or persistent aftertaste can reduce adherence even when the active dose is pharmacologically appropriate.

Taste-masking opportunities

Three approaches are commercially realistic:

1. Sweetener and flavor optimization. This is the lowest-cost approach and is suitable for a generic suspension. It may not adequately mask bitterness at high drug concentration.

2. Polymer or lipid coating. Coated API particles can reduce immediate contact with taste receptors. The coating must dissolve or erode rapidly after swallowing to avoid delayed release or altered bioavailability.

3. Ion-exchange or complexation systems. These can suppress free drug in the mouth but may create new dissolution and bioequivalence risks.

A taste-masked suspension has stronger differentiation potential than a new flavor alone. Flavor changes are easy for competitors to copy and may not support meaningful patent protection.

Administration-device opportunities

The oral suspension can also be differentiated through:

• oral syringes with dose markings appropriate for pediatric volumes
• bottle adapters that reduce spillage
• unit-dose sachets
• ready-to-use packaging
• tamper-evident multidose systems
• packaging that improves resuspension before dosing

Device-based differentiation may produce commercial value even where excipient patent protection is limited. These features can also support hospital, specialty-pharmacy, and caregiver channels.

What generic entry risks exist for rufinamide?

Rufinamide has no biosimilar risk because it is a chemically synthesized small molecule. The relevant competitive threats are ANDA applicants, authorized-generic strategies, and differentiated liquid formulations.

Risk area	Tablet generic	Suspension generic
API sourcing	Moderate	Moderate
Bioequivalence	Moderate	Moderate to high
Excipient matching	Low to moderate	High
Taste-masking differentiation	Low	High
Manufacturing complexity	Low to moderate	Moderate
Device and packaging requirements	Low	Moderate
Formulation patent opportunity	Limited	Higher
Pediatric adherence advantage	Limited	High

The suspension may be more difficult to copy than the tablet because the applicant must match physical stability, preservative performance, dosing uniformity, and sensory characteristics while meeting FDA product-quality standards.

What is the FDA regulatory status and Orange Book position?

Banzel was approved by FDA in 2008. The product received orphan-drug exclusivity for Lennox-Gastaut syndrome, which provided seven years of U.S. market exclusivity for the approved indication. That exclusivity period has expired.[1,2]

The relevant generic pathway is an abbreviated new drug application. An applicant must demonstrate pharmaceutical equivalence and bioequivalence to the applicable reference-listed drug. For the oral suspension, the development burden includes product-quality comparability and the regulatory requirements applicable to liquid oral dosage forms.

FDA’s Orange Book identifies patents and regulatory exclusivity associated with reference-listed drugs. Rufinamide applicants should distinguish between:

• active ingredient patents, which are historical and expired or near-expired depending on jurisdiction and patent-term adjustments;
• formulation patents, which may cover suspension composition, taste masking, or stability;
• method-of-use patents, which may concern seizure treatment or dosing;
• pediatric exclusivity, which can add six months to eligible patent or exclusivity periods;
• orphan exclusivity, which is indication-specific.

A current Orange Book determination requires a live FDA database review for the specific rufinamide reference product, dosage form, and strength. Patent status should not be inferred from the original Banzel approval date alone.[3]

Which companies are challenging or competing with Banzel?

Competition is divided between the Banzel brand, authorized or independent generics, and alternative antiseizure therapies used in Lennox-Gastaut syndrome.

The competitive set includes clobazam, cannabidiol, felbamate, lamotrigine, topiramate, valproate, and other adjunctive therapies. These products do not directly compete on excipients, but they compete for the same prescribing decision and patient adherence budget.

For generic rufinamide, the most credible commercial positions are:

• low-cost 200 mg and 400 mg tablets;
• a directly substitutable 40 mg/mL suspension;
• a better-tasting suspension;
• a smaller-volume pediatric formulation;
• a pharmacy-friendly bottle and dosing device;
• a formulation with improved resuspendability and lower shaking burden.

The strongest launch strategy may combine a conventional tablet ANDA with a differentiated suspension. Tablets provide volume and pharmacy access. The suspension provides higher formulation defensibility and greater potential for brand retention among pediatric patients.

How strong is the patent estate for rufinamide excipients?

The active ingredient estate is substantially less important than formulation execution for current commercial planning. The commercial value of a new excipient composition depends on whether it demonstrates an unexpected technical effect, such as:

• materially improved taste scores;
• reduced sedimentation;
• superior redispersibility after prolonged storage;
• improved stability at elevated temperature;
• reduced food effect;
• improved exposure consistency;
• lower preservative concentration;
• reduced dose volume.

A claim directed only to a particular known sweetener, flavor, suspending agent, or tablet filler is likely to face weak patent defensibility. Stronger claims would combine rufinamide with defined excipient ranges, particle-size limits, manufacturing conditions, and measured performance thresholds.

Patentable formulation concepts

Potential claim categories include:

1. A stable rufinamide suspension with specified particle-size distribution and viscosity.
2. A taste-masked rufinamide particle with a defined polymer coating.
3. A high-concentration suspension with improved redispersibility.
4. A solid oral dosage form with a surfactant-controlled dissolution profile.
5. A formulation with reduced fed-versus-fasted pharmacokinetic variability.
6. A unit-dose pediatric product with defined fill volume and stability characteristics.
7. A manufacturing process that produces consistent assay uniformity at commercial scale.

Method-of-use claims may offer limited protection against generic substitution because ANDA applicants can use a section viii statement for certain non-patented indications when legally available. Formulation claims are more commercially relevant for a differentiated rufinamide product.

When does rufinamide lose exclusivity?

Rufinamide’s U.S. orphan exclusivity period has ended. The timing of generic entry depends on the expiration or enforceability of any listed patents, litigation outcomes, settlement terms, regulatory review, and applicant launch decisions.

Exclusivity category	Rufinamide position
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Expired
Pediatric exclusivity	Historical, if awarded
Patent exclusivity	Must be checked against current Orange Book listings
Biosimilar exclusivity	Not applicable
Generic competition	Legally available subject to listed patents and FDA approval

No single expiration date determines all commercial risk. Tablet and suspension entry can occur on different schedules if the listed patent claims or regulatory requirements differ by dosage form.

What licensing and partnering opportunities exist?

The most attractive licensing targets are formulation technologies rather than rufinamide chemistry.

Potential partners include:

• taste-masking technology companies;
• pediatric liquid developers;
• excipient suppliers with proprietary polymer or lipid systems;
• contract manufacturers with oral-suspension capability;
• specialty-pharmacy distributors;
• companies with established epilepsy portfolios.

A license should be evaluated against four commercial tests: whether the excipient system can support ANDA or 505(b)(2) development, whether the formulation changes food effects, whether the technology has defensible patent claims, and whether the cost of goods remains competitive with standard generics.

An excipient platform that requires expensive coating equipment or specialized raw materials may fail commercially even if it improves taste. Rufinamide’s price-sensitive generic market favors technologies that use conventional manufacturing assets and widely available excipients.

What are the highest-value commercial opportunities?

The leading opportunities rank as follows:

Opportunity	Commercial attractiveness	Main barrier
Directly substitutable tablets	High volume, lower margin	Commodity pricing
Generic 40 mg/mL suspension	Moderate to high	Bioequivalence and stability
Taste-masked pediatric suspension	High differentiation	Clinical and sensory validation
Smaller-volume high-concentration suspension	Moderate	Sedimentation and palatability
Sprinkle or dispersible formulation	Moderate	Product equivalence and dose uniformity
Food-effect-reduced formulation	High strategic value	Pharmacokinetic development
Premium packaging and dosing device	Moderate	Limited patent exclusivity
Modified-release product	Low to moderate	Clinical need and development cost

The best near-term opportunity is a well-controlled pediatric suspension with improved taste, redispersibility, and dosing convenience. The best higher-value opportunity is a formulation that reduces the clinical impact of food-dependent exposure, but this would require a stronger development package and could move beyond a simple ANDA strategy.

Key Takeaways

• Rufinamide’s main excipient opportunity is the oral suspension, not the conventional tablet.
• Pediatric taste masking, suspension stability, and dosing-device design are the highest-value differentiation areas.
• The marketed 40 mg/mL suspension establishes a useful benchmark for concentration and dose volume.
• Food increases rufinamide exposure, creating a potential opportunity for a formulation with lower fed-versus-fasted variability.
• Rufinamide has no biosimilar risk; competition comes from small-molecule generics and alternative Lennox-Gastaut therapies.
• Generic tablets are likely to be more exposed to price competition than differentiated suspensions.
• Formulation patents should claim defined compositions, particle properties, manufacturing parameters, and measured performance results.
• Orphan exclusivity and original regulatory exclusivity have expired, but current Orange Book listings and litigation must be checked before launch planning.

FAQs

Can rufinamide be formulated as a liquid solution?

A true solution is technically more difficult because rufinamide has limited aqueous solubility. A suspension or solubilized system using specialized excipients is more commercially realistic.

What is the most important excipient for rufinamide suspension stability?

No single excipient determines performance. A microcrystalline cellulose-carboxymethylcellulose system, polymeric suspending agent, wetting agent, preservative, and controlled particle-size distribution must work together.

Is a rufinamide taste-masking patent likely to block generic entry?

It could delay or complicate entry if the claims are valid, listed, and enforceable. A generic applicant may avoid the claims by using a different taste-masking mechanism or by launching an unmasked formulation.

Does food-dependent absorption limit rufinamide generic substitution?

Not necessarily. Generic substitution remains possible if the product meets FDA bioequivalence requirements. Food effects increase development and labeling considerations but do not by themselves prevent substitution.

Would a rufinamide orally disintegrating tablet have commercial value?

Potentially, particularly for patients with swallowing difficulty. Its value would depend on taste masking, dose size, rapid dispersion, stability, and whether the product can obtain a commercially practical regulatory pathway.

References

1. U.S. Food and Drug Administration. (2023). Banzel (rufinamide) prescribing information. Eisai Inc. https://www.accessdata.fda.gov
2. U.S. Food and Drug Administration. (2008). FDA approves Banzel for seizures associated with Lennox-Gastaut syndrome. https://www.fda.gov
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm
4. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
5. European Medicines Agency. (2023). Inovelon: EPAR product information. https://www.ema.europa.eu